ArticleVaccine2026
Identification of vaccine candidates by immunization with a complex pool of recombinant VLPs.
Article in Vaccine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Identifying the regions of a protein that can be readily translated into an effective vaccine remains a major challenge in epitope-focused vaccine design, especially when a protein is poorly characterized. Here, we describe an immune-driven strategy for epitope identification which uses the immune system to reveal regions within a candidate protein capable of eliciting targeted antibody responses. Using IL-17A, a pro-inflammatory cytokine, as a model antigen, we engineered a comprehensive library of MS2 bacteriophage virus-like particles (VLPs) displaying peptides representing every possible linear 10-amino acid peptide spanning the 133-amino acid protein. We then used the library to immunize mice, with the hypothesis that a subset of the IL-17A VLP mixture would elicit anti-IL-17A antibody responses. The IL-17A-reactive antibodies elicited by this complex vaccine were then used to select individual recombinant VLPs from the starting library, which were then tested for their ability to elicit anti-IL-17A antibodies in mice. Selected recombinant VLPs were able to elicit anti-IL-17A antibody responses, and antibody levels could be improved by conjugating synthetic peptides representing the selected epitopes to another bacteriophage platform (Qβ VLPs). Overall, this work describes a new method for antigen-agnostic epitope discovery and vaccine development that does not require pre-existing antibodies or rely on computational approaches to identify potential epitopes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.